Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;25(7):620-626.
doi: 10.1634/theoncologist.2019-0863. Epub 2020 Mar 13.

"My Research Is Their Business, but I'm Not Their Business": Patient and Clinician Perspectives on Commercialization of Precision Oncology Data

Kayte Spector-Bagdady  1   2 , Chris D Krenz  2 , Collin Brummel  3 , J Chad Brenner  3   4 , Carol R Bradford  3   4 , Andrew G Shuman  2   3   4
Affiliations

"My Research Is Their Business, but I'm Not Their Business": Patient and Clinician Perspectives on Commercialization of Precision Oncology Data

Kayte Spector-Bagdady et al. Oncologist. 2020 Jul.

Abstract

Background: Genetic sequencing and precision oncology have supported clinical breakthroughs but depend upon access to vast arrays of research specimens and data. One way for academic medical centers to fund such infrastructure and research is "commercialization" of access to specimens and data to industry. Here we explore patient and clinician perspectives regarding cancer specimen and data commercialization with the goal of improving such processes in the future.

Materials and methods: This qualitative analysis was embedded within a prospective precision oncology sequencing study of adults with head and neck cancer. Via semistructured dyadic interviews with patients with cancer and their doctors, we assessed understanding and concerns regarding potential commercialization, opinions regarding investment of profits, and perspectives regarding the return of information directly to participants from industry.

Results: Several patient- and clinician-participants did not understand that the consent form already permitted commercialization of patient genetic data and expressed concerns regarding who would profit from the data, how profits would be used, and privacy and access. Patients were generally more comfortable with commercialization than clinicians. Many patients and clinicians were comfortable with investing profits back into research, but clinicians were more interested in investment in head and neck cancer research specifically. Patients generally supported potential return-of-results from a private entity, but their clinicians were more skeptical.

Conclusion: Our results illustrate the limitations of mandatory disclosures in the informed consent process. The voices of both patients and their doctors are critical to mitigate violations of privacy and a degradation of trust as stakeholders negotiate the terms of academic and commercial engagement.

Implications for practice: Further education is needed regarding how and why specimens and data in precision oncology research may be commercialized for both patients and providers alike. This process will require increased transparency, comprehension, and engagement of involved stakeholders.

Keywords: Commercialization; Data use; Ethics; Industry; Research.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

References

    1. Subbiah V, Kurzrock R. Debunking the delusion that precision oncology is an illusion. The Oncologist 2017;22:881–882. - PMC - PubMed
    1. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease . Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease. Washington, D.C.: National Academies Press, 2011. - PubMed
    1. He KY, Ge D, He MM. Big data analytics for genomic medicine. Int J Mol Sci 2017;18:412. - PMC - PubMed
    1. Cadigan RJ, Lassiter D, Haldeman K et al. Neglected ethical issues in biobank management: Results from a U.S. study. Life Sci Soc Policy 2013;9:1 - PMC - PubMed
    1. Spector‐Bagdady K, De Vries RG, Gornick MG et al. Encouraging participation and transparency in biobank research. Health Aff (Millwood) 2018;37:1313–1320. - PMC - PubMed

Publication types